Kura Oncology, Inc. (NASDAQ:KURA) had its target price lifted by Citigroup Inc. from $15.00 to $19.00 in a report issued on Thursday morning. The brokerage currently has a buy rating on the stock.
Several other brokerages have also recently commented on KURA. Zacks Investment Research cut Kura Oncology from a buy rating to a hold rating in a research report on Friday, September 29th. Cann restated a buy rating on shares of Kura Oncology in a research note on Wednesday. ValuEngine upgraded Kura Oncology from a sell rating to a hold rating in a research note on Friday, September 8th. Finally, Leerink Swann restated an outperform rating and issued a $18.00 price objective (up previously from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $17.20.
Shares of Kura Oncology (NASDAQ KURA) traded up $1.35 during midday trading on Thursday, reaching $16.45. The company had a trading volume of 507,800 shares, compared to its average volume of 338,138. Kura Oncology has a 1 year low of $4.72 and a 1 year high of $16.75. The company has a quick ratio of 10.79, a current ratio of 13.48 and a debt-to-equity ratio of 0.07.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). equities research analysts anticipate that Kura Oncology will post -1.45 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/11/12/kura-oncology-inc-kura-price-target-raised-to-19-00.html.
A number of large investors have recently added to or reduced their stakes in the business. Candriam Luxembourg S.C.A. bought a new stake in Kura Oncology in the third quarter valued at approximately $8,073,000. Vanguard Group Inc. raised its stake in Kura Oncology by 13.0% in the second quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock valued at $4,035,000 after buying an additional 50,033 shares during the period. Morgan Stanley raised its stake in Kura Oncology by 175.5% in the first quarter. Morgan Stanley now owns 430,428 shares of the company’s stock valued at $3,788,000 after buying an additional 274,166 shares during the period. Alethea Capital Management LLC raised its stake in Kura Oncology by 128.1% in the second quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after buying an additional 108,577 shares during the period. Finally, EAM Investors LLC bought a new stake in Kura Oncology in the third quarter valued at approximately $2,884,000. Hedge funds and other institutional investors own 40.56% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.